Halozyme Warns Baxter On Manufacturing Issues

San Diego-based Halozyme Therapeutics said over the weekend that it has delivered notice to Baxter Healthcare, that Baxter is in breach due to failure to provide its HYLENEX (hyaluronidase human injection) product per the firm's development and supply contracts. Halozyme said the move came after Baxter told the firm that certain materials product by Baxter for the firm did not meet requirements of agreements between the firm. Halozyme Therapeutics said that if Baxter is not able to fix the issues within 120 days, it may terminate it relationship with Baxter. Halozyme also said it is working with Baxter and the U.S. FDA to investigate the cause and extent of the manufacturing issues. Halozyme's product is used for pediatric rehydration.